Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 165, Issue 5, 2014, Pages 731-733

  Chen, Christine I ^a   Paul, Harminder ^a   Wang, Trina ^a   Le, Lisa W ^a   Dave, Nimisha ^a   Kukreti, Vishal ^a   Nong Wei, Ellen ^a   Lau, Anthea ^a   Bergsagel, Peter Leif ^b   Trudel, Suzanne ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Chronic lymphocytic leukaemia; IMiDs; Therapy

Indexed keywords

LENALIDOMIDE; ANGIOGENESIS INHIBITOR; THALIDOMIDE;

CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HUMAN; LETTER; LONG TERM EXPOSURE; LOW DRUG DOSE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR CELL DESTRUCTION; TUMOR FLARE; ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84900497281     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12785     Document Type: Letter

References (9)

1. Badoux, X.C., Keating, M.J., Wen, S., Lee, B.N., Sivina, M., Reuben, J., Wierda, W.G., O'Brien, S.M., Faderl, S., Kornblau, S.M., Burger, J.A. & Ferrajoli, A. (2011) Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood, 118, 3489-3498.
2. Chanan-Khan, A., Miller, K.C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C.W., Goodrich, D.W., Bernstein, Z.P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P. & Czuczman, M.S. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology, 24, 5343-5349.
3. Chen, C.I., Bergsagel, P.L., Paul, H., Xu, W., Lau, A., Dave, N., Kukreti, V., Wei, E., Leung-Hagesteijn, C., Li, Z.H., Brandwein, J., Pantoja, M., Johnston, J., Gibson, S., Hernandez, T., Spaner, D. & Trudel, S. (2011) Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. Journal of Clinical Oncology, 29, 1175-1181.
4. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Wierda, W.G., Estrov, Z., Faderl, S., Cohen, E.N., Li, C., Reuben, J.M. & Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297.
5. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, pahse 3 trial. Lancet, 376, 1164-1174.
6. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science, 327, 1345-1350.
7. Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. Chopra, R. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26, 2326-2335.
8. Wendtner, C.M., Hillmen, P., Mahadevan, D., Bühler, A., Uharek, L., Coutré, S., Frankfurt, O., Bloor, A., Bosch, F., Furman, R.R., Kimby, E., Gribben, J.G., Gobbi, M., Dreisbach, L., Hurd, D.D., Sekeres, M.A., Ferrajoli, A., Shah, S., Zhang, J., Moutouh-de Parseval, L., Hallek, M., Heerema, N.A., Stilgenbauer, S. & Chanan-Khan, A.A. (2012) Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma, 53, 417-423.
9. Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.